

Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region - Global Forecast to 2028

Market Report | 2023-04-10 | 254 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The transplant diagnostic market is projected to reach USD 6.8 billion by 2028 from USD 4.4 billion in 2022, at a CAGR of 7.4% during the forecast period. For many patients with chronic dialysis-dependent end-stage renal disease, transplantation is one of their top treatment choices. Additionally, cases involving the heart, liver, and bone marrow can be treated with transplantation. Additionally, over the past ten years, companies have made significant strides in developing better HLA typing technologies, antibody monitoring, tools, and software. This is gradually being used for diagnostic purposes when transplanting various body organs. These are the factors contributing to increasing transplant diagnostic market.

"The Kidney transplants to hold the largest share of the market in 2022"

According to transplant type, the kidney transplant holds the largest market share in 2022. Due to longer lifespans and rising rates of obesity, diabetes, and hypertension, chronic kidney disease is becoming more prevalent and there are more patients needing hemodialysis. These factors are causing an increase in the market share for kidney transplants.

"The Molecular based assay technology is holding the largest share of the market in 2022"

Based on technology, the molecular-based assay technology market is classified into PCR-based Molecular assays and Sequencing based molecular assays. The PCR-based molecular assays hold a larger share than sequencing-based assays like sanger sequencing and NGS sequencing.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"The market in North America region is expected to witness the highest growth during the forecast period."

North America accounted for the largest market share-45.5%-in 2022. The increasing private -public funding and increasing public awareness for organ donation is contributing to the high number of the share of North America.

While APAC is expected to witness significant growth in the coming years. The transplant diagnostic market in the APAC region is expected to register a CAGR of 8.3% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.

A breakdown of the primary participants referred to for this report is provided below:

-□By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%

-□By Designation: C-level-27%, Director-level-18and Others-55%

-□By Region: North America-45%, Europe-15%, Asia Pacific-20%, Latin America-15%, and the Middle East & Africa-5%

The prominent player in transplant diagnostic market are bioMerieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US)

Research Coverage

This report studies the transplant diagnostic market based on product&service, technology,application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

-□Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.

-□Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market..

-□Market Development: Comprehensive information on lucrative emerging regions

-□Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.

-□Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents:

1□INTRODUCTION□	30
1.1□STUDY OBJECTIVES□	30
1.2□MARKET DEFINITION□	30
1.2.1□INCLUSIONS AND EXCLUSIONS□	30
1.3□MARKET SCOPE□	31
1.3.1□MARKETS COVERED□	31
1.3.2□REGIONS COVERED□	32

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.3.3	YEARS CONSIDERED	32
1.4	CURRENCY	32
1.5	STAKEHOLDERS	33
1.6	SUMMARY OF CHANGES	33
2	RESEARCH METHODOLOGY	35
2.1	RESEARCH DATA	35
FIGURE 1	RESEARCH DESIGN: TRANSPLANT DIAGNOSTICS MARKET	35
2.1.1	SECONDARY DATA	36
FIGURE 2	KEY DATA FROM SECONDARY SOURCES	36
2.1.2	PRIMARY DATA	37
FIGURE 3	PRIMARY SOURCES	38
2.1.2.1	Key data from primary sources	39
2.1.2.2	Insights from primary experts	40
2.1.2.3	Breakdown of primaries	40
FIGURE 4	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	41
2.2	MARKET SIZE ESTIMATION	41
FIGURE 5	MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS	42
FIGURE 6	TOP-DOWN APPROACH	43
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	44
FIGURE 7	DATA TRIANGULATION METHODOLOGY	45
2.3.1	METHODOLOGY-RELATED LIMITATIONS	46
2.4	RISK ASSESSMENT	47
TABLE 1	LIMITATIONS AND ASSOCIATED RISKS	47
3	EXECUTIVE SUMMARY	48
FIGURE 8	REAGENTS & CONSUMABLES TO CONTINUE TO DOMINATE TRANSPLANT DIAGNOSTICS MARKET UNTIL 2028	48
FIGURE 9	SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR SEGMENT DOMINATED TRANSPLANT DIAGNOSTICS MARKET IN 2022	49
FIGURE 10	KIDNEY TRANSPLANTATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	50
FIGURE 11	INFECTIOUS DISEASE TESTING SEGMENT TO DOMINATE TRANSPLANT DIAGNOSTIC APPLICATIONS MARKET BY 2028	51
FIGURE 12	INDEPENDENT REFERENCE LABORATORIES TO DOMINATE MARKET DURING FORECAST PERIOD	52
FIGURE 13	REGIONAL SNAPSHOT OF TRANSPLANT DIAGNOSTICS MARKET	53
4	PREMIUM INSIGHTS	55
4.1	TRANSPLANT DIAGNOSTICS MARKET OVERVIEW	55
FIGURE 14	RIISING NUMBER OF TRANSPLANTATION PROCEDURES TO DRIVE MARKET	55
4.2	TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2028 (USD MILLION)	56
FIGURE 15	PCR-BASED MOLECULAR ASSAYS TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	56
4.3	ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SHARE, BY END USER AND COUNTRY (2022)	57
FIGURE 16	INDEPENDENT REFERENCE LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	57
4.4	TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2022 VS. 2028 (USD MILLION)	58
FIGURE 17	HEART TRANSPLANTATION SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	58
4.5	TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY	59
FIGURE 18	CHINA TO WITNESS HIGHEST GROWTH RATE IN TRANSPLANT DIAGNOSTICS MARKET DURING FORECAST PERIOD	59
5	MARKET OVERVIEW	60
5.1	INTRODUCTION	60
5.2	MARKET DYNAMICS	60
FIGURE 19	TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	60
5.2.1	DRIVERS	61
5.2.1.1	Increasing number of transplant procedures	61

5.2.1.2	Technological advancements in transplant diagnostic procedures	61
5.2.1.3	Increasing public-private funding for target research activities	61
TABLE 2 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR DEVELOPMENT OF TRANSPLANT DIAGNOSTIC PRODUCTS, 2018-2022		
5.2.1.4	Rising prevalence of infectious diseases	63
5.2.2	RESTRAINTS	63
5.2.2.1	High procedural cost of NGS- and PCR-based diagnostic assays	63
TABLE 3 EUROPE: COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS (2021)		
5.2.2.2	Limited reimbursement for target procedures	65
TABLE 4 US: MEDICAL REIMBURSEMENTS FOR TRANSPLANTATION PROCEDURES (2021)		
5.2.3	OPPORTUNITIES	66
5.2.3.1	Rising adoption of cross-matching and chimerism testing during pre- & post-transplantation	66
5.2.3.2	Growing public awareness about organ donation and transplantation	66
5.2.4	CHALLENGES	66
5.2.4.1	Significant gap between number of organ donors and organs required annually	66
5.2.4.2	Procedural and technical limitations associated with donor-recipient screening	67
5.3	IMPACT OF RECESSION ON TRANSPLANT DIAGNOSTICS MARKET	67
6	TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY	68
6.1	INTRODUCTION	69
TABLE 5 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)		
6.1.1	MOLECULAR ASSAY TECHNOLOGIES	69
TABLE 6 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2020-2028 (USD MILLION)		
TABLE 7 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)		
TABLE 8 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020-2028 (USD MILLION)		
TABLE 9 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020-2028 (USD MILLION)		
TABLE 10 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020-2028 (USD MILLION)		
6.1.1.1	PCR-BASED MOLECULAR ASSAYS	72
TABLE 11 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)		
TABLE 12 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)		
TABLE 13 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020-2028 (USD MILLION)		
TABLE 14 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2020-2028 (USD MILLION)		
TABLE 15 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)		
6.1.1.1.1	Sequence-specific oligonucleotide-PCR	75
6.1.1.1.1.1	Most widely adopted technique in PCR-based molecular assays market	75
TABLE 16 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2020-2028 (USD MILLION)		
6.1.1.1.2	Sequence-specific primer-PCR	76
6.1.1.1.2.1	Growing public-private investments for research activities to support market growth	76
TABLE 17 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2020-2028 (USD MILLION)		
6.1.1.1.3	Real-time PCR	77
6.1.1.1.3.1	Requires smaller sample volume compared to conventional PCR technologies	77
TABLE 18 TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION, 2020-2028 (USD MILLION)		
6.1.1.1.4	Other PCR-based molecular assays	78

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 19	TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)	78
6.1.1.2	SEQUENCING-BASED MOLECULAR ASSAYS	79
TABLE 20	TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	79
TABLE 21	TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)	80
TABLE 22	TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2020-2028 (USD MILLION)	80
TABLE 23	TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2020-2028 (USD MILLION)	81
TABLE 24	TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)	81
6.1.1.2.1	Sanger sequencing	82
6.1.1.2.1.1	Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market	82
TABLE 25	TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2020-2028 (USD MILLION)	82
6.1.1.2.2	Next-generation sequencing	83
6.1.1.2.2.1	Low turnaround time and high-throughput sequencing to drive adoption of NGS	83
TABLE 26	TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2020-2028 (USD MILLION)	83
6.1.1.2.3	Other sequencing-based molecular assays	83
TABLE 27	TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2020-2028 (USD MILLION)	84
6.1.2	NON-MOLECULAR ASSAY TECHNOLOGIES	84
6.1.2.1	Replacement of non-molecular assay techniques with DNA-based techniques to hamper growth	84
TABLE 28	TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)	85
TABLE 29	TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2020-2028 (USD MILLION)	85
TABLE 30	TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2020-2028 (USD MILLION)	86
TABLE 31	TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2020-2028 (USD MILLION)	86
7	TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE	87
7.1	INTRODUCTION	88
TABLE 32	TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)	88
7.1.1	REAGENTS & CONSUMABLES	88
7.1.1.1	Largest and fastest-growing segment of transplant diagnostics market	88
TABLE 33	TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2020-2028 (USD MILLION)	89
7.1.2	INSTRUMENTS	89
7.1.2.1	Increasing public-private investments to drive market	89
TABLE 34	TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2020-2028 (USD MILLION)	90
7.1.3	SOFTWARE & SERVICES	90
7.1.3.1	Growing automation & digitalization of diagnostic laboratory procedures to support market growth	90
TABLE 35	TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2020-2028 (USD MILLION)	91
8	TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION	92
8.1	INTRODUCTION	93
TABLE 36	TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	93

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.1.1 DIAGNOSTIC APPLICATIONS 93

TABLE 37 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020-2028 (USD MILLION) 94

TABLE 38 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2028 (USD MILLION) 94

8.1.1.1 Pre-transplantation diagnostics 94

TABLE 39 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY TYPE, 2020-2028 (USD MILLION) 95

TABLE 40 PRE-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020-2028 (USD MILLION) 95

8.1.1.1.1 Infectious disease testing 96

8.1.1.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market 96

TABLE 41 INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2020-2028 (USD MILLION) 96

8.1.1.1.2 Histocompatibility testing 96

8.1.1.1.2.1 Technological advancements and growing R&D activities to propel market 96

TABLE 42 HISTOCOMPATIBILITY TESTING MARKET, BY REGION, 2020-2028 (USD MILLION) 97

8.1.1.1.3 Blood profiling 97

8.1.1.1.3.1 Growing availability of molecular assay products to support market growth 97

TABLE 43 BLOOD PROFILING MARKET, BY REGION, 2020-2028 (USD MILLION) 98

8.1.1.2 Post-transplantation diagnostics 98

8.1.1.2.1 Greater risk of disorders and infections post-transplantation makes diagnostics necessary step 98

TABLE 44 POST-TRANSPLANTATION DIAGNOSTICS MARKET, BY REGION, 2020-2028 (USD MILLION) 98

8.1.2 RESEARCH APPLICATIONS 99

8.1.2.1 Growing funding for research to drive market 99

TABLE 45 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2028 (USD MILLION) 99

9 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 100

9.1 INTRODUCTION 101

TABLE 46 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION) 101

9.1.1 INDEPENDENT REFERENCE LABORATORIES 101

9.1.1.1 Rising consolidation of diagnostic laboratories to drive market 101

TABLE 47 TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2020-2028 (USD MILLION) 102

9.1.2 HOSPITALS & TRANSPLANT CENTERS 102

9.1.2.1 Growing purchasing power of hospitals & transplant centers to support market growth 102

TABLE 48 TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2020-2028 (USD MILLION) 103

9.1.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 103

9.1.3.1 Increasing industry-academia collaborations in genomics-based transplant diagnostic research to drive market 103

TABLE 49 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2020-2028 (USD MILLION) 104

10 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 105

10.1 INTRODUCTION 106

TABLE 50 TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION) 106

10.1.1 SOLID ORGAN TRANSPLANTATION 106

TABLE 51 SOLID ORGAN TRANSPLANTATION MARKET, BY TYPE, 2020-2028 (USD MILLION) 107

TABLE 52 SOLID ORGAN TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION) 107

10.1.1.1 Kidney transplantation 108

10.1.1.1.1 Rising prevalence of kidney diseases to drive market 108

FIGURE 20 NUMBER OF KIDNEY TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028 108

TABLE 53 KIDNEY TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION) 109

10.1.1.2 Liver transplantation 109

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1.1.2.1	Growing patient population with chronic liver diseases and increasing procedural volume to drive market	109
FIGURE 21	NUMBER OF LIVER TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028	110
TABLE 54	LIVER TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	110
10.1.1.3	Lung transplantation	110
10.1.1.3.1	Rising prevalence of chronic lung diseases to drive market	110
FIGURE 22	NUMBER OF LUNG TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028	111
TABLE 55	LUNG TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	111
10.1.1.4	Heart transplantation	111
10.1.1.4.1	Increasing prevalence of chronic cardiac diseases to propel market	111
FIGURE 23	NUMBER OF HEART TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028	112
TABLE 56	HEART TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	112
10.1.1.5	Pancreas transplantation	113
10.1.1.5.1	Procedural complexity and risk of surgical complications to restrain growth	113
FIGURE 24	NUMBER OF PANCREAS TRANSPLANTATION PROCEDURES IN MAJOR MARKETS, 2022 VS. 2028	113
TABLE 57	PANCREAS TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	114
10.1.1.6	Other organ transplantation	114
TABLE 58	OTHER ORGAN TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	114
10.1.2	STEM CELL TRANSPLANTATION	115
10.1.2.1	Rising procedural volume and growing research activities to drive market	115
TABLE 59	STEM CELL TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	115
10.1.3	SOFT TISSUE TRANSPLANTATION	116
10.1.3.1	Technological advancements and rising prevalence of target diseases to drive market	116
TABLE 60	SOFT TISSUE TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	116
10.1.4	BONE MARROW TRANSPLANTATION	116
10.1.4.1	Dearth of well-trained surgeons to perform bone marrow transplantation to hinder growth	116
TABLE 61	BONE MARROW TRANSPLANTATION MARKET, BY REGION, 2020-2028 (USD MILLION)	117
11	TRANSPLANT DIAGNOSTICS MARKET, BY REGION	118
11.1	INTRODUCTION	119
TABLE 62	TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2028 (USD MILLION)	119
11.1.1	NORTH AMERICA	119
FIGURE 25	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT	120
TABLE 63	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	121
TABLE 64	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	121
TABLE 65	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	122
TABLE 66	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	122
TABLE 67	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)	123
TABLE 68	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	123
TABLE 69	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)	124
TABLE 70	NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)	124
11.1.1.1	US	125
11.1.1.1.1	Technological advancements in transplant diagnostics to drive market	125
FIGURE 26	US: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019-2021	125
TABLE 71	US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	126
TABLE 72	US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	126
TABLE 73	US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD	

MILLION)127

11.1.1.2Canada127

11.1.1.2.1Growing availability of transplant diagnostic products to support market growth127

FIGURE 27CANADA: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019-2021127

TABLE 74CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)128

TABLE 75CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)128

TABLE 76CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)129

11.1.2EUROPE129

TABLE 77EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)130

TABLE 78EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)130

TABLE 79EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)131

TABLE 80EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)131

TABLE 81EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)132

TABLE 82EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)132

TABLE 83EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)133

TABLE 84EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)133

11.1.2.1GERMANY134

11.1.2.1.1Largest market for transplant diagnostics in Europe134

TABLE 85GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)134

TABLE 86GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)135

TABLE 87GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)135

11.1.2.2UK136

11.1.2.2.1Rising number of transplantation procedures to drive market136

TABLE 88UK: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021136

TABLE 89UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)136

TABLE 90UK: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)137

TABLE 91UK: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)137

11.1.2.3France138

11.1.2.3.1Increased adoption of molecular diagnostic techniques for donor-recipient compatibility testing to propel market138

TABLE 92FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)138

TABLE 93FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)139

TABLE 94FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)139

11.1.2.4Spain140

11.1.2.4.1Rising number of solid organ transplantation procedures to drive market140

TABLE 95SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)140

TABLE 96SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)141

TABLE 97SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 141

11.1.2.5 Italy 142

11.1.2.5.1 Sluggish growth in healthcare sector to restrain market growth 142

TABLE 98 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION) 142

TABLE 99 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 143

TABLE 100 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 143

11.1.2.6 Rest of Europe 144

TABLE 101 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION) 144

TABLE 102 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 145

TABLE 103 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 145

11.1.3 ASIA PACIFIC 145

FIGURE 28 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT 146

TABLE 104 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION) 147

TABLE 105 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION) 147

TABLE 106 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 148

TABLE 107 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 148

TABLE 108 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION) 149

TABLE 109 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION) 149

TABLE 110 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION) 150

TABLE 111 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION) 150

11.1.3.1 China 151

11.1.3.1.1 Improvements in healthcare infrastructure to support market growth 151

TABLE 112 CHINA: ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021 151

TABLE 113 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION) 151

TABLE 114 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 152

TABLE 115 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 152

11.1.3.2 India 153

11.1.3.2.1 Increasing number of transplantation procedures to drive market 153

TABLE 116 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION) 153

TABLE 117 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 153

TABLE 118 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 154

11.1.3.3 Japan 154

11.1.3.3.1 Rising prevalence of chronic diseases to support market growth 154

FIGURE 29 JAPAN: SOLID ORGAN TRANSPLANTATION PROCEDURES, 2019-2021 154

TABLE 119 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION) 155

TABLE 120 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION) 155

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 121	JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	156
11.1.3.4	Australia	156
11.1.3.4.1	Rising number of solid organ transplantation procedures to drive market	156
TABLE 122	AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	156
TABLE 123	AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	157
TABLE 124	AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	157
11.1.3.5	South Korea	158
11.1.3.5.1	Government initiatives to introduce medical coverage for transplantation to drive market	158
TABLE 125	SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	158
TABLE 126	SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	159
TABLE 127	SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	159
11.1.3.6	Rest of Asia Pacific	159
TABLE 128	REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	160
TABLE 129	REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	160
TABLE 130	REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	161
11.1.4	LATIN AMERICA	161
TABLE 131	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (USD MILLION)	162
TABLE 132	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	162
TABLE 133	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	163
TABLE 134	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	163
TABLE 135	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)	164
TABLE 136	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	164
TABLE 137	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)	165
TABLE 138	LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)	165
11.1.4.1	Brazil	166
11.1.4.1.1	Rising investments by leading transplant diagnostic manufacturers to favor market growth	166
TABLE 139	BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	166
TABLE 140	BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	167
TABLE 141	BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	167
11.1.4.2	Mexico	168
11.1.4.2.1	Rising medical tourism to support market growth	168
TABLE 142	MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	168
TABLE 143	MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	169
TABLE 144	MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	169

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.4.3	Rest of Latin America	170
TABLE 145	REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	170
TABLE 146	REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	170
TABLE 147	REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	171
11.1.5	MIDDLE EAST & AFRICA	171
11.1.5.1	Developing healthcare infrastructure to favor market growth	171
TABLE 148	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2028 (USD MILLION)	172
TABLE 149	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	172
TABLE 150	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2020-2028 (USD MILLION)	173
TABLE 151	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2028 (USD MILLION)	173
TABLE 152	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 (USD MILLION)	174
TABLE 153	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2028 (USD MILLION)	174
TABLE 154	MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2028 (USD MILLION)	175
12	COMPETITIVE LANDSCAPE	176
12.1	INTRODUCTION	176
12.2	STRATEGIES ADOPTED BY KEY PLAYERS	176
FIGURE 30	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET	177
12.3	MARKET SHARE ANALYSIS	178
FIGURE 31	TRANSPLANT DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021	178
12.4	COMPETITIVE SCENARIO	179
12.4.1	PRODUCT LAUNCHES AND APPROVALS	179
12.4.2	DEALS	179
12.5	COMPETITIVE LEADERSHIP MAPPING	180
12.5.1	STARS	181
12.5.2	EMERGING LEADERS	181
12.5.3	PERVASIVE PLAYERS	181
12.5.4	PARTICIPANTS	181
FIGURE 32	TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021	182
13	COMPANY PROFILES	183
13.1	KEY PLAYERS	183
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*		
13.1.1	BIO-RAD LABORATORIES	183
TABLE 155	BIO-RAD LABORATORIES: COMPANY OVERVIEW (2021)	183
FIGURE 33	BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)	184
13.1.2	F. HOFFMANN-LA ROCHE LTD.	188
TABLE 156	F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW (2021)	188
FIGURE 34	F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)	189
13.1.3	QIAGEN NV	192
TABLE 157	QIAGEN NV: COMPANY OVERVIEW (2021)	192
FIGURE 35	QIAGEN NV: COMPANY SNAPSHOT (2021)	193
13.1.4	BECTON, DICKINSON AND COMPANY	199
TABLE 158	BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW (2021)	199

FIGURE 36 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 200

13.1.5 BIOFORTUNA 202

13.1.6 BIOMERIEUX SA 203

TABLE 159 BIOMERIEUX SA: COMPANY OVERVIEW (2021) 203

FIGURE 37 BIOMERIEUX SA: COMPANY SNAPSHOT (2021) 204

13.1.7 CAREDx 206

TABLE 160 CAREDx: COMPANY OVERVIEW (2021) 206

FIGURE 38 CAREDx: COMPANY SNAPSHOT (2021) 207

13.1.8 GENDx 210

TABLE 161 GENDx: COMPANY OVERVIEW (2021) 210

13.1.9 HOLOGIC, INC. 212

TABLE 162 HOLOGIC, INC.: COMPANY OVERVIEW (2021) 212

FIGURE 39 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 213

13.1.10 ILLUMINA, INC. 215

TABLE 163 ILLUMINA, INC.: COMPANY OVERVIEW (2021) 215

FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2021) 216

13.1.11 IMMUCOR, INC. 219

TABLE 164 IMMUCOR, INC.: COMPANY OVERVIEW (2021) 219

FIGURE 41 IMMUCOR, INC.: COMPANY SNAPSHOT (2021) 220

13.1.12 LUMINEX CORPORATION 224

TABLE 165 LUMINEX CORPORATION: COMPANY OVERVIEW (2021) 224

FIGURE 42 LUMINEX CORPORATION: COMPANY SNAPSHOT (2021) 225

13.1.13 MERCK KGAA 227

TABLE 166 MERCK KGAA: COMPANY OVERVIEW (2021) 227

FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021) 228

13.1.14 OMIXON 229

TABLE 167 OMIXON: COMPANY OVERVIEW (2021) 229

13.1.15 THERMO FISHER SCIENTIFIC 231

TABLE 168 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW (2021) 231

FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 232

13.2 OTHER PLAYERS 235

13.2.1 ALPHABIOTECH LIMITED 235

13.2.2 BAG DIAGNOSTICS GMBH 236

13.2.3 HANSA BIOPHARMA AB 237

13.2.4 HISTOGENETICS LLC 237

13.2.5 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 238

13.2.6 TBG DIAGNOSTICS LIMITED 239

13.2.7 TAKARA BIO INC. 240

13.2.8 INNO-TRAIN DIAGNOSTIK GMBH 241

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX 242

14.1 DISCUSSION GUIDE 242

14.2 KNOWLEDGESTORE: MARKETSandMARKETS SUBSCRIPTION PORTAL 257

14.3 CUSTOMIZATION OPTIONS 259

14.4 RELATED REPORTS 259

14.5 AUTHOR DETAILS 260

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing),
Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen
Detection), Type (Heart, Kidney, Liver, Bone Marrow), End User & Region - Global
Forecast to 2028**

Market Report | 2023-04-10 | 254 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>